NEW YORK, May 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Where are antithrombotic and anticoagulant treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022.
How will products - Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra, Aspirin Cardio, Effient, Pradaxa, Brilinta and others - perform? Our report gives you business research and analysis with many sales predictions. See the future of the industry and market.
Also, receive forecasting of submarkets, finding potential sales trends from 2012:
• Platelet aggregation inhibitors
• Vitamin K antagonists
• Direct thrombin inhibitors
• Direct factor Xa inhibitors.
Our report discusses activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies.
What does the future hold? With its R&D pipelines, the pharma industry has potential for improved treatments and increased revenues from blood-thinning ag
Copyright©2010 PR Newswire.
All rights reserved